---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-24-007035"
form_type: "8-K"
ticker: "ESPR"
cik: "0001434868"
company_name: "Esperion Therapeutics, Inc."
filed_at: "2024-02-27T23:59:59+00:00"
generated_at: "2026-06-05T11:25:13.716092+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Esperion Q4/FY23 revenue growth 72%/54%; litigation resolved with $100M payment; FDA PDUFA March 31

## Summary
- FY23 U.S. net product revenue $78.3M (+40% YoY); total revenue $116.3M (+54% YoY).
- Q4 U.S. net product revenue $20.8M (+39% YoY); total revenue $32.3M (+72% YoY).
- Litigation with DSE resolved; $100M received Jan 2024, additional $25M pending EMA label determination.
- FDA PDUFA date March 31, 2024 for CV risk reduction label; Otsuka JNDA filing on track for 2024.
- Cash position boosted by $90.8M net equity offering and $100M litigation payment; 2024 OpEx guidance $225-245M.

## SEC filing metadata
- accession: 0001628280-24-007035
- form_type: 8-K
- ticker: ESPR
- cik: 0001434868
- company_name: Esperion Therapeutics, Inc.
- filed_at: 2024-02-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434868/000162828024007035/0001628280-24-007035-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434868/000162828024007035/espr-20240227.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-24-007035
- JSON: https://secwatch.observer/filing/0001628280-24-007035.json
- Plain text: https://secwatch.observer/filing/0001628280-24-007035.txt

## Key facts
- Earnings Releases
  Esperion Therapeutics, Inc. reported fourth quarter and full year ended December 31, 2023 results: revenue $32.3 million for the three months ended December 31, 2023, and $116.3 million for the full year ended December 31, 2023.
  - Period: fourth quarter and full year ended December 31, 2023
  - Revenue: $32.3 million for the three months ended December 31, 2023, and $116.3 million for the full year ended December 31, 2023
  - Result: reported results
  source text: Esperion (NASDAQ: ESPR) today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1434868/000162828024007035/0001628280-24-007035-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.